Showing results (1161-1170 of 1,547) with videos related to

Sort By:
Pageof 155
Neuro-Oncology|November 11, 2017
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913Prakash Chinnaiyan, Minhee Won, Patrick Y Wen, et al.
British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Neuro-Oncology|April 10, 2024
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO reviewLakshmi Nayak, Chetan Bettegowda, Florian Scherer, et al.
Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Neuro-Oncology|February 12, 2011
Clinical trial end points for high-grade glioma: the evolving landscapeDavid A Reardon, Evanthia Galanis, John F DeGroot, et al.
Neuro-Oncology|September 2, 2015
A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningiomaAyal A Aizer, Malak Abedalthagafi, Wenya Linda Bi, et al.
Neuro-Oncology|July 31, 2022
EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumorsRoberta Rudà, David Capper, Adam D Waldman, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2025
A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eREACH2): study protocolE Mastaglio, B Egleston, K T Lee, et al.
ESMO Open|December 3, 2025
Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)L Dercle, S Geyer, A B Nixon, et al.
Pageof 155